In
general immunoassays, secondary antibodies are covalently linked
with enzymes and bind to the Fc region of target-bound primary antibodies
to amplify signals of low-abundant target molecules. The antibodies
themselves are obtained from large mammals and are further modified
with enzymes. In this study, we developed novel recombinant immunoglobulin
G (IgG)-binding luciferase-based signal amplifiers (rILSAs) by genetically
fusing luciferase (Nluc) with antimouse IgG1 nanobody (MG1Nb) and
antibody-binding domain (ABD), individually or together, in a mix-and-match
manner. We obtained three different highly pure rILSAs in large quantities
using a bacterial overexpression system and one-step purification.
Mouse-specific rILSA, MG1Nb-Nluc, and rabbit-specific rILSA, Nluc-ABD,
selectively bound to target-molecule-bound mouse IgG1 and rabbit IgG
primary antibodies, whereas the bispecific rILSA, MG1Nb-Nluc-ABD,
mutually bound to both mouse IgG1 and rabbit IgG primary antibodies.
All rILSAs exhibited an outstanding signal-amplifying capability comparable
to those of conventional horseradish-peroxidase-conjugated secondary
antibodies, regardless of the target molecules, in various immunoassay
formats, such as enzyme-linked immunosorbent assay, Western blot,
and lateral flow assays. Each rILSA was selected for its own individual
purpose and applied to various types of target analytes, in combination
with a variety of target-specific primary antibodies, effectively
minimizing the use of animals as well as reducing the costs and time
associated with the production and chemical conjugation of signal-amplifying
enzymes.